CapStar Financial Holdings is a bank holding company. Through its subsidiary, CapStar Bank, the company is engaged as a bank that seeks to establish and maintain relationships with its clients by delivering banking solutions and client service. The company's products and services include commercial real estate loans, private banking and wealth management services for the owners and operators of its business clients and other individuals and correspondent banking services for Tennessee's smaller community banks. The company provides deposit products and services, including demand deposits, interest-bearing transaction accounts, time and savings deposits, certificates of deposit and CDARS? reciprocal products.

Christopher & Banks is a specialty retailer featuring women's apparel and accessories. The company's merchandise assortments include women's apparel, consisting of casual clothing, everyday basics, wear-to-work, leisure / active wear, and seasonal sleepwear in missy, petite and women sizes. The company's Christopher and Banks (CB) stores provides merchandise assortments in women's apparel and accessories for missy and petite sizes. The company's C.J. Banks (CJ) stores provides merchandise assortments in women's apparel and accessories for women's sizes. The company's Missy, Petite, Women and outlet stores, and its website provides merchandise assortments from both CB and CJ in all three ranges.

Idera Pharmaceuticals is a biopharmaceutical company. The company utilizes two proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor (TLR); and its nucleic acid. The company's TLR drug candidates are: IMO-2125, an indication for Anti-PD1 Refractory Metastatic Melanoma and Refractory Solid Tumors; and IMO-8400, an indication for Dermatomyositis. The company's Nucleic Acid Chemistry research programs comprised of: IDRA-008, for treatment of Familial Chylomicronemia Syndrome and Familial Partial Lipodystrophy; Nucleic Acid Chemistry Compound, an indication for renal disease; and IMO-9200, an indication for non-malignant Gastrointestinal Disorders.

International Flavors & Fragrances is a creator and manufacturer of taste, scent and complementary adjacent products, including cosmetic active and natural health ingredients. The company's operating segments are Taste and Scent. The Taste segment develops a range of different flavors and taste offerings for its customers, most of which are tailor-made. The company's Taste business is comprised of various portfolios across flavor compounds, savory solutions, inclusions and nutrition and specialty ingredients. The Scent segment creates fragrance compounds and fragrance ingredients for the household and personal care products. The company also produces cosmetic active and functional ingredients for use in cosmetics.

Macquarie Infrastructure is a holding company. The company owns and operates a portfolio of businesses that provide services to other businesses, government agencies and individuals primarily in the U.S. The businesses the company owns and operate are: International-Matex Tank Terminals, which provides bulk liquid terminalling services to third parties in the U.S. and in Canada; Atlantic Aviation, which provides fuel, terminal, aircraft hangaring and other services primarily to owners and operators of general aviation jet aircraft at airports throughout the U.S.; and MIC Hawaii, which consist of energy company that processes and distributes gas and provides related services.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.